V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240014563 | 240008969 | 1.76 | 94.2 | Palliative (P) | 2018-07-03 | 2018-07-11 | ESHAP | N | N | 240030629 | IVE |
| 240014564 | 240012793 | 1.72 | 90 | Curative (C) | 2015-06-03 | 2016-01-06 | CISPLATIN + FLUOROURACIL | 02 | N | 240030743 | RCEOP |
| 240014565 | 240012794 | 1.62 | 81.8 | Palliative (P) | 2018-02-09 | 2018-02-18 | CARBOPLATIN + RT | 02 | N | 240031120 | IGEV R |
| 240014566 | 240008978 | 0 | 67.5 | Curative (C) | 2016-01-21 | 2016-01-21 | AML 18 TRIAL | 02 | N | 240031751 | TRIPLE INTRATHECAL |
| 240014567 | 240008980 | 1.66 | 77.7 | Palliative (P) | 2013-11-24 | 2015-04-18 | CHLORAMBUCIL + OFATUMUMAB | N | N | 240031958 | LEGEND TRIAL |
| 240014568 | 240012796 | 1.65 | 57.4 | Not known (9) | 2017-04-16 | 2017-04-16 | Vinorelbine IV | 2 | N | 240032004 | REMODL TRIAL |
| 240014569 | 240012797 | 1.7 | 64.6 | Curative (C) | 2016-12-19 | 2016-12-19 | Etoposide oral | 2 | N | 240032220 | CAV |
| 240014570 | 240014585 | 1.66 | 84 | Palliative (P) | 2016-05-31 | 2016-06-02 | AML17 TRIAL | 1 | N | 240032239 | CRIZOTINIB |
| 240014571 | 240015937 | null | null | Disease modification (D) | 2015-01-13 | 2015-01-16 | VEDex | N | N | 240032251 | CISPLATIN + PACLITAXEL |
| 240014572 | 240012799 | 1.57 | 62.6 | Palliative (P) | 2018-03-15 | 2018-04-06 | MABCUTE TRIAL | N | N | 240032654 | OFATUMUMAB |
| 240014573 | 240008985 | null | 94.2 | Palliative (P) | 2015-12-09 | 2015-12-11 | OFATUMUMAB | N | N | 240032654 | VEDEX |
| 240014574 | 240012800 | null | null | null | 2013-12-23 | 2013-12-29 | ETOPOSIDE | 02 | null | 240032911 | PIXANTRONE |
| 240014575 | 240008988 | 1.49 | 70.8 | Curative (C) | 2018-02-17 | 2018-03-03 | DOXORUBICIN | N | N | 240033354 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 240014576 | 240008991 | 1.64 | 45.3 | Palliative (P) | 2014-02-25 | 2014-06-08 | PEMBROLIZUMAB | N | N | 240033903 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 240014577 | 240008992 | null | 60.9 | Disease modification (D) | 2015-01-17 | 2015-01-20 | BENDAMUSTINE + BORTEZOMIB | N | N | 240034000 | CARBOPLATIN + DOCETAXEL |
| 240014578 | 240008993 | 0 | 140 | Curative (C) | null | 2014-03-24 | AML17 TRIAL | N | Y | 240034037 | ATG + BUSULFAN + FLUDARABINE |
| 240014579 | 240008997 | 1.57 | 52.6 | Palliative (P) | 2016-04-30 | 2016-05-13 | AML17 TRIAL | N | N | 240034474 | MITOXANTRONE |
| 240014580 | 240008998 | 0 | 91.4 | Palliative (P) | 2018-10-09 | 2018-10-16 | CARMUSTINE + THIOTEPA | 02 | N | 240035260 | CYTARABINE + METHOTREXATE |
| 240014581 | 240008999 | 1.72 | 60 | Palliative (P) | 2019-07-05 | 2019-07-17 | Carboplatin + Vinorelbine Oral | N | N | 240035558 | AML19 TRIAL |
| 240014582 | 240014591 | 1.53 | 51.3 | Curative (C) | 2017-09-06 | 2017-09-06 | GEM-P | N | N | 240035615 | CYTARABINE HIGH DOSE |
| 240014583 | 240009002 | 1.63 | 88 | Palliative (P) | 2016-10-27 | 2016-11-24 | TOPOTECAN | N | N | 240004804 | VEDEX |
| 240014584 | 240009003 | 1.84 | 91.6 | Curative (C) | 2018-12-22 | 2018-12-22 | CODOX M | N | N | 240004804 | CLOFARABINE + CYTARABINE |
| 240014585 | 240012810 | 1.58 | 76 | Palliative (P) | 2017-09-18 | 2017-09-19 | Carboplatin + Vinorelbine Oral | 02 | N | 240006774 | VINORELBINE |
| 240014586 | 240009006 | 1.72 | 70.5 | Neo-adjuvant (N) | 2018-11-22 | 2018-11-23 | CVP | 2 | N | 240006808 | CVP |
| 240014587 | 240009009 | 1.82 | 82.2 | Curative (C) | 2015-02-23 | 2015-02-23 | DA-EPOCH-R | Y | N | 240009311 | BLEOMYCIN + CHLORAMBUCIL + LOMUSTINE + METHOTREXATE + RITUXIMAB + VINBLASTINE |
| 240014588 | 240009010 | 1.52 | null | Palliative (P) | 2016-10-12 | 2017-02-01 | VINCRISTINE | N | N | 240011413 | FAB LMB |
| 240014589 | 240009012 | 1.68 | 56.1 | Curative (C) | 2017-11-05 | 2017-11-05 | CAV | Y | N | 240012412 | ICE-R |
| 240014590 | 240009014 | 1.67 | 67 | Curative (C) | 2016-01-26 | 2016-01-27 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB | 1 | N | 240015382 | IVE |
| 240014591 | 240009016 | 1.77 | 0 | Disease modification (D) | 2013-07-21 | 2014-03-23 | CISPLATIN + GEMCITABINE | 02 | N | 240016293 | CAPECITABINE + IRINOTECAN |
| 240014592 | 240009018 | 1.72 | null | Palliative (P) | 2016-04-30 | 2016-06-14 | R CODOX M | null | N | 240019083 | CAV |
| 240014593 | 240009020 | 1.63 | 79.5 | Curative (C) | 2017-03-06 | 2017-03-13 | CYTARABINE + METHOTREXATE | 2 | N | 240019885 | PILOT TRIAL |
| 240014594 | 240009020 | 0 | 49 | Curative (C) | 2014-07-05 | 2014-07-17 | CVP | 2 | N | 240019885 | BEVACIZUMAB + CARBO + DOCETAXEL |
| 240014595 | 240009021 | null | 81.2 | Palliative (P) | 2015-06-04 | 2015-06-04 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | N | null | 240021157 | CYTARABINE + ETOPOSIDE |
| 240014596 | 240009024 | 1.7 | 73.5 | Palliative (P) | 2017-07-02 | 2017-07-11 | Cytarabine HD + Methotrexate HD | N | N | 240021819 | R CODOX-M/ R IVAC |
| 240014597 | 240012822 | 1.92 | 76.2 | Curative (C) | 2017-10-02 | 2017-10-05 | CLADRIBINE | 2 | N | 240022190 | CISPLATIN + GEMCITABINE + RITUXIMAB |
| 240014598 | 240009027 | 1.57 | 59.7 | Disease modification (D) | 2016-08-02 | 2016-08-25 | R-GEM-P | N | null | 240022466 | DABRAFENIB + TRAMETINIB |
| 240014599 | 240009030 | 1.72 | 100.65 | null | 2015-11-30 | 2015-12-12 | Bevacizumab+Carbo+Gemcitabine | N | N | 240023588 | IMATINIB |
| 240014600 | 240009032 | 1.74 | 64.5 | Curative (C) | 2018-05-22 | 2018-05-22 | CYTARABINE + METHOTREXATE + RITUXIMAB | N | N | 240025395 | TOPOTECAN |
| 240014601 | 240009034 | null | 54.6 | Palliative (P) | 2014-09-22 | 2014-09-29 | Bortezomib + MELPHALAN | N | N | 240030474 | MPV |
| 240014602 | 240015488 | null | null | Palliative (P) | null | 2019-08-16 | Triple / Double Intrathecal Therapy | N | N | 240034505 | PIXANTRONE |
| 240014603 | 240012827 | 1.57 | 69.1 | Curative (C) | 2017-06-30 | 2017-12-05 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | 240015030 | CISPLATIN + MITOMYCIN |
| 240014604 | 240005497 | null | 87 | null | null | 2015-11-27 | Rituximab (Maintenance) | N | N | 240000030 | RITUXIMAB |
| 240014605 | 240011018 | 1.56 | 82 | Palliative (P) | 2018-02-23 | 2018-03-03 | Rituximab (Maintenance) | 02 | N | 240000035 | RITUXIMAB |
| 240014606 | 240005506 | 1.68 | null | Adjuvant (A) | 2015-03-15 | 2015-08-15 | Rituximab (Maintenance) | N | N | 240000092 | RITUXIMAB |
| 240014607 | 240005511 | 1.69 | 60.5 | Palliative (P) | 2017-08-28 | 2017-08-31 | Rituximab (SUBCUTANEOUS Maintenance) | N | N | 240000133 | RITUXIMAB |
| 240014608 | 240005514 | 1.65 | 91.1 | Disease modification (D) | 2017-05-09 | 2017-05-09 | Rituximab | 02 | Y | 240000161 | RITUXIMAB |
| 240014609 | 240005522 | null | 99.699 | null | 2016-06-03 | 2016-06-27 | Rituximab (Maintenance) | null | null | 240000246 | RITUXIMAB |
| 240014610 | 240005529 | 1.73 | null | Curative (C) | 2017-08-31 | 2017-12-19 | Rituximab | N | N | 240000300 | RITUXIMAB |
| 240014611 | 240005535 | 1.71 | 102.3 | Disease modification (D) | null | 2016-02-15 | Rituximab | N | N | 240000359 | RITUXIMAB |
| 240014612 | 240005541 | 1.52 | 69.6 | Neo-adjuvant (N) | 2017-03-01 | 2017-03-06 | Rituximab (Maintenance) | 2 | N | 240000439 | RITUXIMAB |